Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials
Stroke 38:874-880, Akins,P.T.,et al, 2007
Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
JAMA 293:690-698,736, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, 2005
Increasing Prevalence of Vascular Risk Factors in Patients with Stroke
Neurol 89:1985-1994, Otite, F.O.,et al, 2017
Apixaban in Patients With Atrial Fibrillation
NEJM 364:806-817, Connolly,S.J.,et al, 2011
Chronic Heart Failure and Ischemic Stroke
Stroke 42:2977-2982, Haeusler, K.G.,et al, 2011
Direct Thrombin Inhibition and Stroke Prevention in Elderly Patients With Atrial Fibrillation: Experience From the SPORTIF III and V Trial
Stroke 38:2965-2971, Ford,G.A.,et al, 2007
Stroke Prevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin in Patients with Non-Valvular Atrial Fibrillation (SPORTIF III): Randomised Controlled Trial
Lancet 362:1691-1698,1686, Executive Steering Committee on Behalf of the SPOR, 2003
10 Most Commonly Asked Questions About Which Antiplatelet Agent to Prescribe
The Neurologist 9:318-322, Adams,H.P. Jr., 2003
Stroke in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction
Neurol 54:288-294, Pullicini,P.M.,et al, 2000
Failure of Aspirin Treatment After Stroke
Stroke 25:275-277, Bornstein,N.M.,et al, 1994
Predictors of Thromboembolism in Atrial Fibrillation:I. Clinical Features of patients at Risk
The Stroke Prevention in A Fib Investigators, Ann Int Med 116:1-51992., , 1992
Role of Ticlopidine for Prevention of Stroke
Stroke 23:912-916, Albers,G.W., 1992
Ticlopidine
Editorial, Lancet 337:459-4601991., , 1991